Ramzi Khamis

Prof Ramzi Y. J. Khamis is the Wu Family Endowed Chair of Cardiology at Imperial College London and Consultant Interventional Cardiologist at Imperial College Healthcare NHS Trust, where he leads the High-Risk Atherosclerosis and Cardio-Immune Clinic. He previously served as Clinical Director of Cardiology and Cardiothoracic Surgery at the Trust.

His clinical expertise lies in interventional cardiology and the management of high-risk atherosclerosis. His research focuses on the role of immunity in cardiovascular disease and the development of novel imaging modalities to characterise vascular inflammation, with a particular emphasis on translation into clinical practice. He is Chairman of the Imperial Vulnerable Plaque and Patient (VPM) Meeting, which convenes leaders from academia, industry and clinical practice to advance cardiovascular prevention and treatment of the vulnerable atherosclerotic plaque.

Prof Khamis lectures widely and leads collaborative programmes in translational cardiovascular medicine. He qualified in Bristol in 2000, trained at Barts and The London, and completed both his PhD and specialist cardiology training at Imperial College London. He has been awarded multiple national and international prizes for his research and was appointed full professor at Imperial in 2024.

Selected Publications:

1. Hartley A, Rostamian S, Kaura A, Chrysostomou P, Welsh P, Ariti C, Sattar N, Sever P, Khamis RY. The relationship of baseline high-sensitivity C-reactive protein with incident cardiovascular events and all-cause mortality over 20 years. EBioMedicine. 2025;117:105786. doi: 10.1016/j.ebiom.2025.105786. PubMed: 40472800. PubMed
2. Hajhosseiny R, Hartley A, Cole G, Muñoz C, Sethi A, Al-Lamee R, Khawaja S, Zaman S, Howard J, Gopalan D, Ariff B, Kaprielian R, Neji R, Kunze KP, Kaura A, Prieto C, Khamis R, Botnar RM. Free-breathing, non-contrast, three-dimensional whole-heart coronary magnetic resonance imaging for the identification of culprit and vulnerable atherosclerotic plaque. J Cardiovasc Magn Reson. 2025;27(1):101898. doi: 10.1016/j.jocmr.2025.101898. PubMed/PMC: 40274104 / PMC12135368. PubMed
3. Hartley A, Williams MC, Kaura A, Caga-Anan M, Dey D, Dweck MR, Haskard DO, Newby DE, Khamis RY. Antimalondialdehyde low-density lipoprotein antibody levels predict low-attenuation plaque in the SCOT-HEART trial. JACC: Cardiovascular Imaging. 2024;17(1):98–100. doi: 10.1016/j.jcmg.2023.07.006. PubMed: 37656117. PubMed
4. van den Berg VJ, Haskard DO, Fedorowski A, Hartley A, Kardys I, Caga-Anan M, Akkerhuis KM, Oemrawsingh RM, van Geuns RJ, de Jaegere P, van Mieghem N, Regar E, Ligthart JMR, Umans VAWM, Serruys PW, Melander O, Boersma E, Khamis RY. IgM anti-malondialdehyde low-density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). EBioMedicine. 2018;36:63–72. doi: 10.1016/j.ebiom.2018.08.023. PubMed/PMC: 30131305 / PMC6197783. PubMed

For a full and continuously updated list of publications and academic activity:
Imperial College London – Prof Ramzi Khamis: https://www.imperial.ac.uk/people/r.khamis